secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zenas BioPharma, Inc. (ZBIO)
CIK:        0001953926
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001104659-24-124616
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zenas provides obexelimab trial updates: Ph3 INDIGO topline end-2025, Ph2 data 2025-2026
--------------------------------------------------------------------------------

- Phase 3 INDIGO trial in IgG4-RD fully enrolled (over 190 patients); topline results expected year-end 2025.
- Phase 2 MoonStone trial in RMS enrolling; 12-week primary endpoint data expected Q3:2025.
- Phase 2 SunStone trial in SLE enrolling; 24-week primary endpoint data expected 1H:2026.
- Preliminary interim data from Cohort 1 of Phase 2 SApHiAre trial in wAIHA provided.
- Company states capitalized for clinical data readouts into Q4:2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1953926/000110465924124616/0001104659-24-124616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1953926/000110465924124616/tm2429902d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-124616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer